SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment

Adjuvant tamoxifen reduces the recurrence rate of estrogen receptor (ER)-positive breast cancer. Previous in vitro studies have suggested that tamoxifen can affect the cancerous inhibitor of protein phosphatase 2A (CIP2A)/protein phosphatase 2A (PP2A)/phosphorylation Akt (pAkt) signaling in ER-negat...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Yu-Hsiang, Chu, Pei-Yi, Chen, Ji-Lin, Huang, Chun-Teng, Lee, Chia-Han, Lau, Ka-Yi, Wang, Wan-Lun, Wang, Yu-Ling, Lien, Pei-Ju, Tseng, Ling-Ming, Liu, Chun-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162815/
https://www.ncbi.nlm.nih.gov/pubmed/30154367
http://dx.doi.org/10.3390/jcm7090245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162815/
https://www.ncbi.nlm.nih.gov/pubmed/30154367
http://dx.doi.org/10.3390/jcm7090245

Ejemplares similares